Company performance
Current Price
as of Dec 10, 2024$312.77
P/E Ratio
N/A
Market Cap
$6.82B
Description
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
Metrics
Overview
- HQWest Conshohocken, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerMDGL
- Price$312.77-1.78%
Trading Information
- Market cap$6.82B
- Float84.30%
- Average Daily Volume (1m)388,682
- Average Daily Volume (3m)408,486
- EPS-$25.07
Company
- Revenue$76.81M
- Rev growth (1yr)N/A
- Net income-$106.96M
- Gross margin96.06%
- EBITDA margin-186.58%
- EBITDA-$116.01M
- EV$3.73B
- EV/Revenue48.57
- P/EN/A
- P/S88.55
- P/B8.78
Documents
SEC Filings
Earnings Calls
Factset Street Account